The settlement followed government intervention in a qui tam suit alleging Alphama paid kickbacks in the form of sham consulting arrangements, payments for attendance at meetings and so-called educational grants in order to increase sales of Kadian, a morphine-based drug, according to the release.
Read the release on the Alpharma settlement.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
